Here are 1-3 brief analogies for Arcutis Biotherapeutics (ARQT):

• Like AbbVie, but exclusively focused on developing topical treatments for skin diseases.
• Imagine Johnson & Johnson, but purely dedicated to prescription dermatology.

• ARQ-151: A topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
• ARQ-154: A topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis.
• ARQ-252: A selective topical janus kinase type 1 inhibitor developed for hand eczema and vitiligo.
• ARQ-255: A topical formulation of ARQ-252 designed to reach deeper into the skin to treat alopecia areata.

Arcutis Biotherapeutics (ARQT) is a biopharmaceutical company that develops and commercializes prescription treatments for dermatological diseases. As such, it sells its products primarily to other companies within the pharmaceutical supply chain, rather than directly to individual patients.

The major customers for a biopharmaceutical company like Arcutis typically include large drug wholesalers and distributors, which then supply pharmacies, hospitals, and clinics. While specific contractual details are not publicly disclosed, the primary "major customers" for a company commercializing pharmaceutical products in the United States would be the major pharmaceutical wholesalers. These companies purchase drugs in bulk from manufacturers and distribute them to points of care.

The major customer companies that Arcutis Biotherapeutics would likely sell its products to are:

• McKesson Corporation (Symbol: MCK)
• AmerisourceBergen Corporation (Symbol: ABC)
• Cardinal Health, Inc. (Symbol: CAH)

Frank Watanabe, President and Chief Executive Officer

Mr. Watanabe has served as the President of Arcutis since 2016 and Chief Executive Officer since 2017. Prior to joining Arcutis, he was the co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company, and previously served as Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals. He held executive roles at Amgen Inc. from 2005 to 2013, and at Eli Lilly and Company starting in 1996. Mr. Watanabe also served as an official in the U.S. government and was a commissioned officer in the U.S. Navy Reserves for 25 years. He has served on the board of Amunix Pharmaceuticals.

Latha Vairavan, Chief Financial Officer

Ms. Vairavan was promoted to Chief Financial Officer in May 2025, overseeing all financial operations for Arcutis. She joined Arcutis in 2020 and has held positions of increasing responsibility, including Executive Director of Financial Planning and Analysis and Vice President, Finance and Corporate Controller. With over 20 years of finance and accounting experience in the biotech industry, Ms. Vairavan previously spent 12 years at Amgen, where she held various finance roles, ultimately serving as finance director for U.S. value and access. She began her career as a financial consultant with KPMG and Arthur Andersen.

Patrick Burnett, MD, PhD, FAAD, Executive Vice President, Chief Medical Officer

Dr. Burnett was promoted to Executive Vice President, Chief Medical Officer in December 2024 and joined Arcutis in August 2020. A dermatologist, he previously served as Chief Medical Officer at Verrica Pharmaceuticals since April 2018. Prior to that, Dr. Burnett was Associate Vice President of Clinical Development at Sun Pharmaceuticals from September 2015 to March 2018, where he oversaw the dermatology and rheumatology pipeline, and was a Global Program Medical Director at Novartis from 2010 to August 2015.

L. Todd Edwards, Executive Vice President, Chief Commercial Officer

Mr. Edwards was promoted to Executive Vice President, Chief Commercial Officer in December 2024 and joined Arcutis in September 2023. He brings over 25 years of experience in sales, marketing, market access, and general management. Before Arcutis, he was Group Vice President and Business Unit Head of Immunology at Incyte, where he led the successful launch and commercialization of a topical JAK inhibitor for atopic dermatitis. Mr. Edwards also spent nearly eight years at UCB as Senior Vice President and Head of Global Immunology Operations and Strategy, and held senior roles at AbbVie and TAP Pharmaceuticals.

Todd Tucker, Chief Human Resources Officer

Mr. Tucker serves as the Chief Human Resources Officer at Arcutis, having joined the company in July 2020 as Executive Director of HR. Prior to Arcutis, he was the Senior Director of Total Rewards at Atara Biotherapeutics. He also held the role of Senior Director and Head of Human Resources at Sienna Biopharmaceuticals, where he established and led the human resources function during the company's transition from a private to a publicly traded entity.

Key Risks to Arcutis Biotherapeutics (ARQT)

1. Reliance on ZORYVE (roflumilast) and Pipeline Success: Arcutis Biotherapeutics' financial performance and competitive position are heavily dependent on the successful commercialization of its lead product, ZORYVE (roflumilast), and the development and regulatory approval of its other pipeline candidates. Setbacks such as delays in regulatory approvals, failure to achieve market acceptance, or intense competition for ZORYVE or its other product candidates could significantly impact the company. Several sources highlight that the company's valuation is largely tied to its overall pipeline, and its heavy dependence on the ZORYVE franchise is considered a primary business risk.
2. Financial Viability and High Operating Expenses: Arcutis Biotherapeutics faces ongoing financial challenges, including a significant accumulated deficit and persistent net losses, driven by substantial expenses related to research, development, and commercialization efforts. The company anticipates continuing to incur losses and significant expenses as it advances its product candidates and expands the market reach of ZORYVE. Its reliance on capital markets for additional financing to support operations and strategic initiatives poses a risk; an inability to secure necessary funds could lead to operational constraints.
3. Intense Industry Competition and Regulatory Hurdles: The biopharmaceutical industry, particularly in dermatology, is highly competitive, with Arcutis contending against larger companies possessing more substantial resources. Furthermore, the company's product candidates must navigate complex and evolving regulatory landscapes. Delays or denials in regulatory approvals for new indications or pipeline drugs could hinder commercialization efforts and impact the company's ability to bring new therapies to market.

Arcutis Biotherapeutics (ARQT) focuses on developing and commercializing treatments for various dermatological diseases. The addressable markets for their main product candidates are as follows:

• ARQ-151 (roflumilast cream) for Plaque Psoriasis: The U.S. plaque psoriasis market size was approximately USD 14,000 million in 2023. The global plaque psoriasis treatment market was expected to be worth USD 18.0 billion in 2022 and projected to grow at a 10.0% CAGR from 2023 to 2029.
• ARQ-151 (roflumilast cream) for Atopic Dermatitis: The global atopic dermatitis drugs market size was estimated at USD 17.64 billion in 2024 and is projected to reach USD 29.88 billion by 2030. In the U.S., the atopic dermatitis drugs industry generated USD 4.7 billion in 2023.
• ARQ-154 (roflumilast foam) for Seborrheic Dermatitis: The global seborrheic dermatitis market size was valued at USD 2.95 billion in 2024 and is expected to reach USD 6.80 billion by 2032.
• ARQ-154 (roflumilast foam) for Scalp Psoriasis: While a specific market size for scalp psoriasis alone was not available, it is a form of psoriasis. Plaque psoriasis, the most common type of psoriasis, accounts for 80%-90% of all psoriasis cases. The market for scalp psoriasis is therefore encompassed within the broader psoriasis or plaque psoriasis market, as noted above.
• ARQ-252 (selective topical janus kinase type 1 inhibitor) for Hand Eczema: The 7 major chronic hand eczema markets (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) reached a value of USD 12.6 Billion in 2024. The chronic hand eczema market size in the U.S. accounted for nearly USD 431 million in 2023.
• ARQ-252 (selective topical janus kinase type 1 inhibitor) for Vitiligo: The market size for vitiligo in the 7MM (United States, EU4 countries, United Kingdom, and Japan) was found to be USD 1.1 billion in 2024. The United States accounted for approximately 61% of this total market size in 2024.
• ARQ-255 (topical formulation of ARQ-252) for Alopecia Areata: The global alopecia areata market size is calculated at USD 3.32 billion in 2024 and is expected to be worth USD 6.92 billion by 2034. In the U.S., the alopecia areata market size was around USD 202 million in 2023.

Arcutis Biotherapeutics (ARQT) is expected to drive future revenue growth over the next two to three years through several key initiatives centered around its flagship product, ZORYVE (roflumilast), and its expanding pipeline.

Here are the expected drivers of future revenue growth:

1. Continued Robust Growth of ZORYVE Across Approved Indications: Arcutis anticipates sustained and significant sales growth for its ZORYVE portfolio (cream and foam formulations) for already approved indications, including plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The company has provided strong full-year net product sales guidance for 2026, initially ranging from $455 million to $470 million, which was later raised to between $480 million and $495 million. ZORYVE is strategically positioned as a leading non-steroidal topical treatment, aiming to capture market share from traditional topical corticosteroids.
2. Expansion of ZORYVE into New Patient Populations and Indications: A significant driver will be the expansion of ZORYVE's label to new age groups and additional dermatological conditions. The FDA approved ZORYVE cream 0.05% for atopic dermatitis in children as young as two years old in October 2025, broadening its addressable market. Additionally, a supplemental New Drug Application (sNDA) for ZORYVE cream 0.3% for plaque psoriasis in children aged 2 to 5 years has a Prescription Drug User Fee Act (PDUFA) target action date of June 2026. The company also expects to submit an sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis in Q2 2026, following positive Phase 2 trial results. Beyond these, Arcutis is exploring new indications with Phase 2 proof-of-concept studies for ZORYVE foam in vitiligo and hidradenitis suppurativa, with potential advancement decisions in late 2026 and early 2027, respectively.
3. Enhanced Commercialization and Market Access Efforts: Arcutis is investing in its commercial capabilities to deepen the adoption of ZORYVE. This includes a targeted approximately 20% expansion of its dermatology sales force in 2026 to optimize prescriber targeting and call frequency. Furthermore, the company has secured Medicare access for ZORYVE beginning January 2026, providing non-preferred access for about one in three Medicare patients. Arcutis is also taking over direct sales and promotion of ZORYVE in pediatric and primary care settings with a dedicated sales team, following the termination of a promotion agreement with Kowa. Improved gross-to-net pricing and strong reimbursement rates are also contributing factors.
4. Advancement of the Pipeline Beyond Roflumilast: While ZORYVE remains the primary focus, Arcutis is also advancing its pipeline with new molecules. The company initiated a Phase 1a/1b clinical study for ARQ-234, a CD200R agonist, in healthy volunteers and adults with atopic dermatitis in March 2026. Although early-stage, this program represents a potential future revenue stream beyond the roflumilast franchise and could contribute to diversifying the company's product offerings and reducing its reliance on a single product over the longer term.

Share Repurchases

No information available on share repurchase programs or actual repurchases within the last 3-5 years.

Share Issuance

• In February 2021, Arcutis announced an underwritten public offering of $150.0 million of its common stock.
• In February 2026, the company filed an omnibus shelf registration for multiple securities, establishing flexible funding tools for future needs.

Inbound Investments

No specific large inbound investments by third-parties were identified within the last 3-5 years.

Outbound Investments

No information available on outbound investments or acquisitions made by Arcutis Biotherapeutics.

Capital Expenditures

• Capital expenditures for the last 12 months (prior to March 2026) were approximately -$686,000.
• In Q4 2025, capital expenditures were reported as $0.
• Capital investments are generally focused on long-term assets and infrastructure to support the company's research and development efforts and commercialization of dermatological treatments.